This technology introduces 2D material-doped peptide-imprinted polymers for ultra-sensitive Parkinson’s detection. Merging epitope imprinting with MXenes/TMDs, we create a biomimetic platform targeting alpha-synuclein and LRRK2. It delivers high sensitivity, low detection limits, and superior stability compared to natural antibodies. This cost-effective electrochemical sensor is ideal for rapid point-of-care testing (POCT), facilitating early diagnosis and personalized PD management.

This technology pioneers 2D material-doped peptide-imprinted polymers to overcome traditional Parkinson＇s detection limits. Two core innovations: 1) Integrating epitope imprinting with electropolymerization to forge stable, low-cost "artificial antibodies" from short peptides. 2) Doping with 2D materials (MXenes/TMDs) to massively boost surface area and electron transfer. This amplifies electrochemical signals, enabling ultra-sensitive, rapid POCT for early diagnosis.

This technology solves the high cost and fragility of traditional Parkinson＇s antibody tests. Our 2D material-doped imprinted polymers enable ultra-sensitive, rapid point-of-care testing (POCT). Ideal for hospitals, home care, and drug screening. Currently partnered with Biotegy Corp. and advancing a Lithuania joint project, this scalable platform holds immense commercial value, accelerating the realization of accessible precision neuro-diagnostics.